11 October 2023
11 October 2023
The Scottish Medicines Consortium accepted 12 new treatments for conditions ranging from cancer to obesity.
The study authors noted that early combination therapy is recommended in T2D patients with inadequately controlled hyperglycemia
Sanofi will make an upfront cash payment and near-term payments to BioMap for reaching module development milestones.
Robots are already vital in a number of sectors, from manufacturing to retail, and their use will only grow.
The partnership builds on their existing drug discovery agreement to develop a neurological disease target.
The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.
The US Food and Drug Administration granted fast-track designation for the DOC1021 vaccine.
The logistics service is taking another step in becoming a leader in healthcare and pharmaceutical logistics.
Join us on October 17th, as Boris Baňas and Jan Storch discuss the challenges of sourcing certified cannabis for clinical trials and delve into CB21 Pharma's cannabis-derived product portfolio.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
